Bio Stock Doc

Biodel: Creating A Better, Faster Acting Insulin, The Next Big Thing For Diabetic Therapy

This article will focus on the Ultra-Fast-Acting Insulin segment as a whole and specifically, we will examine the recent trial data from Biodel (NASDAQ:BIOD), a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes a growing therapeutic area worldwide and a $10-$12 billion segment in the US alone.

Advantages of Ultrafast insulin (there are many)

A) Better glycemic control

Faster, higher insulin concentrations and peak exposure (i.e., fast in) results in early glucose lowering effects and reduced post-meal hyperglycemia, which may lead to better A1C control

B) Less hypoglycemia

Reduced late post-meal exposure (i.e., fast out) may result in fewer hypoglycemic events

C) Less weight gain (a huge plus)

Fewer hypoglycemic events and

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details